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Abstract Because estrogen contributes to the promotion
and progression of breast cancer, a greater understanding of
the role of estrogen in breast cancer has led to therapeutic
strategies targeting estrogen synthesis, the estrogen recep-
tor, and intracellular signaling pathways. The enzyme
aromatase catalyses the ﬁnal step in estrogen biosynthesis
and was identiﬁed as an attractive target for selective
inhibition. Modern third-generation aromatase inhibitors
(AIs) effectively block the production of estrogen without
exerting effects on other steroidogenic pathways. The
discovery of letrozole (Femara
1) achieved the goal of
discovering a highly potent and totally selective AI.
Letrozole has greater potency than other AIs, including
anastrozole, exemestane, formestane, and aminoglutethi-
mide. Moreover, letrozole produces near complete
inhibition of aromatase in peripheral tissues and is asso-
ciated with greater suppression of estrogen than is achieved
with other AIs. The potent anti-tumor effects of letrozole
were demonstrated in several animal models. Studies with
MCF-7Ca xenografts successfully predicted that letrozole
would be clinically superior to the previous gold standard
tamoxifen and also indicated that it may be more effective
than other AIs. An extensive program of randomized
clinical trials has demonstrated the clinical beneﬁts of le-
trozole across the spectrum of hormone-responsive breast
cancer in postmenopausal women.
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Introduction
Studies have consistently shown that lifetime exposure to
estrogens increases the risk of breast cancer [1]. The degree
of risk is increased by persistently elevated blood con-
centrations of estrogen [2]; clinical indicators of
persistently elevated blood estrogen concentrations, for
example, age at menarche, ﬁrst live birth, menopause,
alcohol consumption, and obesity [3–5]; and, although still
controversial, exposure to exogenous estrogen, for exam-
ple, some forms of hormone replacement therapy and oral
contraceptives [6–12]. The presence of some of these
factors also increases the risk of breast cancer being
estrogen receptor (ER)-positive [13]. Studies have shown
that higher levels of endogenous estrogen and testosterone
(which is converted to estrogen by aromatase) increases
breast cancer risk, regardless of predicted breast cancer risk
[14–16]. These data indicate that estrogen is an important
risk factor even in women considered at high risk of
developing the disease, for example, those with a family
history of breast cancer.
Estrogen is thought to contribute to the initiation and
contributes to the promotion and progression of breast
cancer via two complementary mechanisms [1], the car-
cinogenic effects of estrogen metabolites, notably hydroxyl
metabolites [3, 17, 18], and stimulation of ER signaling
pathways, including those initiated by activation of epi-
dermal growth factors, notably the mitogen-activated
phosphoinositide 3 kinase pathway [19–30]. Greater
understanding of the role of estrogen in breast cancer has
led to therapeutic strategies targeting estrogen synthesis
(aromatase inhibitors [AIs]) [31], the ER (selective ER
modulators [SERMs], pure antagonists) [32], and intra-
cellular signaling pathways (signal transduction inhibitors)
[33].
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those with ER or progesterone receptor (PgR) expression
detectable above a pre-set limit [34]. Patients whose ER or
PgR expression is below this pre-set limit are considered
HR–. Approximately two thirds of breast cancer patients
have HR+ tumors [13] and are candidates for treatment
strategies designed to counteract the growth effects of
estrogen. This review describes the rational development of
the potent AI letrozole, which has therapeutic utility in
HR+ tumors across the breast cancer continuum.
Mechanism of action of aromatase inhibitors
Aromatase
Aromatase (cytochrome P-450 [CYP] 19) catalyzes the
rate-limiting step (conversion of steroidal C-19 androgens
to C-18 estrogens) in estrogen biosynthesis [35–37]. Aro-
matization is the ﬁnal step in steroid biosynthesis (Fig. 1)
[38]; and, therefore, aromatase is an attractive target for
selective inhibition [39, 40]. Aromatase is expressed pri-
marily in the ovary and also in central and peripheral
tissues, fat, muscle, liver, and breast [41, 42]. With
increasing age, as ovarian estrogen production declines
[43], the contribution of peripheral production of estrogens
increases [44], and in postmenopausal women, peripheral
aromatization of androstenedione produced by the adrenal
gland (Fig. 1)[ 38] becomes the main source of endogenous
estrogens [45–49]. Of note, normal and malignant breast
tissue contributes to the peripheral synthesis of estrogens
[14, 50–53]. Thus, expression of aromatase in breast
tumors may contribute signiﬁcantly to the degree of cel-
lular exposure to estrogens [14]; therefore, it is important
to target both intra-tumoral and peripheral aromatase [31].
The presence of intracellular aromatase activity could
explain why estrogen concentrations are 10–20 times
higher in peripheral tissue than blood in postmenopausal
but not pre-menopausal women [41, 54–58]. Moreover,
estrogen concentrations are higher in tumors than in sur-
rounding non-malignant tissue [41, 54–58]. Recent
research has increased understanding of how aromatase is
regulated by tissue-speciﬁc promoters [59] and how genetic
variation may affect the pathophysiology of estrogen-
dependent disease [60]. Pharmacogenomics may become
an increasingly important tool for individualizing hormonal
therapy for patients with breast cancer.
Aromatase inhibitors
Modern third-generation AIs effectively block the pro-
duction of estrogen without exerting effects on other
steroidogenic pathways and have been heralded as a ‘‘tri-
umph of translational oncology’’ [61]. The search for
potent and selective inhibitors of aromatase started with the
ﬁrst-generation inhibitor aminoglutethimide [62]. How-
ever, aminoglutethimide lacked selectivity for aromatase
[63] and inhibited biosynthesis of cortisol, aldosterone, and
thyroid hormone [64] as well as aromatase; moreover,
aminoglutethimide was also found to induce hepatic
enzymes (Fig. 2)[ 65, 66]. Second-generation AIs included
the nonsteroidal inhibitor fadrozole and the steroidal
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Fig. 1 Aromatization of androgens to estrogens in postmenopausal
women. A androstenedione, E1 estrone, E1S estrone sulfate, E2
estradiol, T testosterone. Reprinted from [38] with permission from
the Society of Endocrinology
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Fig. 2 The development of aromatase inhibitors (AIs) has culmi-
nated in agents with high speciﬁcity and potency for aromatase.
Spectrum of action of ﬁrst- through third-generation AIs: The third-
generation AIs act exclusively on the aromatase enzyme and do not
appear to exert additional effects. Potency of AIs determined by
degree of inhibition of total body aromatase: 4-OHA 4-hydroxyandr-
ostenedione. Reprinted from [66] with permission from the Society of
Endocrinology
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123inhibitor formestane (4-hydroxyandrostenedione). Fadroz-
ole was superior to aminoglutethimide in terms of potency,
selectivity, and safety [67], but its selectivity was not
complete and clinical trials suggested that it was no more
effective than tamoxifen [68, 69].
To improve on fadrozole, Novartis synthesized a series
of new compounds. Structure-activity relationship studies
were then performed to identify the most potent AI from a
series of benzyl-azole derivatives of fadrozole [70]. The
third-generation AI letrozole (Femara
1) was the result of
this structure-activity approach to drug design and
achieved the research goal of creating a highly potent and
totally selective AI [71]. These compounds were also used
to design pioneering molecular modeling techniques used
to map the active site of aromatase [70, 72]. Other third-
generation AIs developed during this period were the
nonsteroidal agents vorozole (since discontinued) and an-
astrozole [73] (Fig. 2)[ 66] and the steroidal agent
exemestane [74]. AIs have been classiﬁed as steroidal (type
I; for example, exemestane) or nonsteroidal (type II; for
example, letrozole and anastrozole) [75]. A comprehensive
review of AIs focuses on the pharmacology and clinical
development of letrozole [76].
Letrozole pharmacodynamics and pharmacokinetics
Potency
The chemical structure of letrozole (4,40-[(1H-1,2,4-triazol-
1-yl) methylene] bis-benzonitrile) is compared with other
AIs in Fig. 3 [77]. The nitrogen-containing structures like
the imidazoles and the triazoles bind to the iron in the heme
moiety of CYP-450, whereas the cyanobenzyl moiety
present in the nonsteroidal AIs such as letrozole partially
mimics the steroid backbone of the enzyme’s natural sub-
strate androstenedione. Furthermore, the triazole
compound letrozole was found to be superior to other
derivatives of fadrozole in terms of in vivo inhibition of
aromatase [70].
Letrozole is a highly potent inhibitor of aromatase in
vitro, in vivo in animals, and in humans. The relative
potencies of letrozole, anastrozole, and fadrozole were
determined in a variety of model cellular endocrine and
tumor systems containing aromatase (hamster ovarian tis-
sue fragments, adipose tissue ﬁbroblasts from normal
human breast, the MCF-7Ca human breast cancer cell line
transfected with the human aromatase gene, and the JEG-3
human choriocarcinoma cell line) [31]. These studies
showed that although letrozole and anastrozole are
approximately equipotent in a cell-free aromatase system
(human placental microsomes), letrozole is 10–30 times
more potent than anastrozole in inhibiting intracellular
aromatase in intact rodent cells, normal human adipose
ﬁbroblasts, and human cancer cell lines (Fig. 4)[ 31]. In
several other studies, letrozole has consistently demon-
strated greater potency compared with anastrozole,
exemestane, formestane, and aminoglutethimide (Table 1)
[31, 71, 75, 78–82].
The degree of aromatase inhibition can be determined in
vivo by measuring uterine weight after treatment with a
standard dose of androstenedione in immature female rats
[71]. Using this assay, it was found that the in vivo potency
of letrozole is more than four orders of magnitude greater
than aminoglutethimide (50% effective dose [ED50],
1–3 lg/kg vs. 30 mg/kg, respectively) [71]. It has also
been shown that neoadjuvant letrozole profoundly inhibits
in situ aromatase activity and reduces endogenous
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123estrogens within the breast in postmenopausal women with
large primary breast cancers [75].
In postmenopausal women, letrozole achieves signiﬁ-
cantly greater plasma estrogen suppression of estrogens
and greater inhibition of in vivo aromatization than anas-
trozole [83]. In the study, levels of aromatase were
detectable in 11 of 12 patients during treatment with an-
astrozole (mean percentage inhibition in the whole group,
97.3%) but in none of the 12 patients during treatment with
letrozole ([99.1% suppression in all patients; Wilcoxon,
P = 0.0022, comparing the two drug regimens). Suppres-
sion of estrone and estrone sulfate was found to be
signiﬁcantly greater during treatment with letrozole com-
pared with anastrozole (P = 0.019 and 0.0037,
respectively). Another study conducted in 54 postmeno-
pausal women with invasive breast cancer showed that
more complete inhibition of aromatase was achieved with
2.5 mg of letrozole than 1 mg of anastrozole, resulting in
signiﬁcantly greater suppression of estradiol (P\0.0001),
the most bioactive estrogen [84]. This recent study con-
ﬁrms previous observations showing that letrozole
produces near complete inhibition of aromatase in periph-
eral tissues, associated with greater suppression of estrogen
than achieved with other AIs [78, 85–90].
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Fig. 4 Relative potencies with which letrozole, anastrozole, and
fadrozole inhibit aromatase from non-cellular and intracellular
sources. Reprinted from [31] with permission from Elsevier
Table 1 Inhibitory concentrations of letrozole, anastrozole, exemestane, fadrozole, 4-hydroxyandrostenedione and aminoglutethimide against
the aromatase enzyme derived from various cellular and non-cellular sources. Reprinted from [77] with permission from Elsevier
Aromatase
inhibitor
IC50 values (nM), (relative potency; letrozole = 1)
Human
placental
microsomes
Particulate
fractions of
human breast
cancer
Rat ovarian
microsomes
MCF-7Ca
cancer cells
JEG-3
cancer cells
CHO
cells
Hamster
ovarian
tissue
Human
breast
Letrozole 2 (1) 0.8 (1)
Anastrozole 8 (0.25) 15 (0.053)
Exemestane 15 (0.13) 5 (0.16)
4-OHA 30 (0.07) 30 (0.027)
AG 20,000 (0.0001) 10,000 (0.0008)
Letrozole 11 (1) 0.07 (1) 0.07 (1) 20 (1) 0.8 (1)
Anastrozole 23 (0.48) 0.82 (0.085) 0.99 (0.071) 600 (0.033) 14 (0.057)
Fadrozole 5 (2.2) 0.05 (1.4) 0.07 (1.0) 30 (0.67) 1 (0.80)
4-OHA 62 (0.18)
AG 1900 (0.0058)
Letrozole 1.02 (1) 0.35 (1.0) 0.45 (1) 0.14 (1)
Anastrozole 5.35 (0.19) 3.62 (0.097) 5.66 (0.080) 17.17 (0.0082)
4-OHA 0.59 (0.59) 1.6 (0.28) 0.72 (0.19)
Letrozole 7 (1)
Anastrozole 25 (0.28)
Fadrozole 7 (1)
Letrozole 1.4 (0)
Anastrozole 27 (0.052)
4-OHA 60 (0.023)
AG 5500 (0.00025)
4-OHA 4-hydroxyandrostenedione, AG aminoglutethimide
Values quoted are IC50 values representing the concentration needed to achieve 50% inhibition of aromatase activity. The relative potency of
each inhibitor compared with letrozole is shown in parentheses
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Letrozole is highly selective for aromatase and unlike ﬁrst-
and second-generation AIs does not signiﬁcantly affect
cortisol, aldosterone, or thyroxine [77]. In vitro studies
showed that letrozole was more than three orders of mag-
nitude more selective than aminoglutethimide in its effects
on progesterone and corticosterone production, and more
than 300-fold more selective against aldosterone than
fadrozole [71, 78]. In vivo adrenocorticotrophic hormone
(ACTH) stimulation tests in rats showed that letrozole had
no signiﬁcant effect on either aldosterone or corticosterone
levels, even at a dose 1,000 times greater than that required
for inhibition of aromatase [71].
The selectivity of letrozole has been demonstrated in
clinical studies in postmenopausal women. These studies
showed that letrozole has no effect on the plasma levels of
17a-OH progesterone, thyroid-stimulating hormone (TSH),
luteinizing hormone (LH), follicle-stimulating hormone
(FSH), or androstenedione and does not affect normal urine
electrolyte excretion or thyroid function [86, 91–93]. Of
note, the vast majority of patients treated with letrozole
have a normal response to synthetic ACTH [86].
Anti-tumor activity in vivo
The potent anti-tumor effects of letrozole have been
demonstrated in several animal models [77, 78, 94].
Letrozole induced complete regression of estrogen-depen-
dent, 9,10-dimethylbenz-a-anthracene (DMBA)-induced
mammary tumors in adult female rats [95]. The ED50 for
letrozole was determined to be 10–30 lg/kg/day.
The use of MCF-7 cells transfected with human aro-
matase gene (MCF-7Ca) and implanted into athymic nude
mice has proved to be an effective in vivo model for pre-
dicting clinical results with AIs [61, 96, 97]. Using this
model, it has been shown that letrozole produces dose-
dependent inhibition of tumor growth, resulting in com-
plete inhibition at a daily dose of 10 lg/animal/day [94,
98]. Comparative studies using the MCF-7Ca model have
shown that letrozole is more effective at suppressing tumor
growth than the pure anti-estrogen fulvestrant and the
SERM tamoxifen [99]. While anastrozole was also better
than fulvestrant and tamoxifen in suppressing tumor
growth, only letrozole was shown to induce tumor regres-
sion [99].
Another study, also using the MCF-7Ca model, dem-
onstrated that letrozole potently inhibits mammary tumor
growth but does not have the estrogenic effects of tamox-
ifen, as measured by its uterotrophic effects [100]. The
observation that tamoxifen has an agonist effect even when
estrogen synthesis is inhibited by letrozole suggests that
there may be a degree of antagonism between these com-
pounds [100]. Interestingly, studies in the MCF-7Ca model
showed that letrozole is more effective as monotherapy
than when combined with tamoxifen [80, 101]. In the study
reported by Long et al. [101] tumor volume doubling times
were 3–4 weeks in controls, 16 weeks with tamoxifen
alone, 18 weeks with tamoxifen plus letrozole, and
34 weeks with letrozole alone. First-line treatment with
letrozole was shown to be signiﬁcantly superior to treat-
ment with tamoxifen alone or with the two drugs combined
(at week 16, both P\0.001). Tumors that progressed
during treatment with tamoxifen remained sensitive to
second-line letrozole therapy, whereas tumors that pro-
gressed on letrozole did not respond to second-line
treatment with tamoxifen or fulvestrant. In another series of
experiments conducted by the same group using the MCF-
7Ca model, letrozole was even effective as third-line
therapy for a limited period when administered after
treatment with tamoxifen and exemestane [102]. The
studies showed that although exemestane was more effec-
tive than tamoxifen in controlling tumor growth, letrozole
as ﬁrst-line therapy was the most effective treatment
overall, both in terms of the degree of tumor suppression
and the length of effectiveness of treatment [102].
The potential of letrozole as a chemopreventive agent
was investigated in an in vivo model using aromatase-
transgenic female mice [103]. The model provided evi-
dence to show that aromatase overexpression is sufﬁcient
to induce and maintain early preneoplastic and neoplastic
changes that can be completely abrogated by treatment
with letrozole. Carcinogenicity studies have also found that
letrozole decreases the incidence of spontaneous mammary
tumors and granular cell tumors in rats [104].
Pharmacokinetics of letrozole
Clinical pharmacokinetic studies of letrozole have been
conducted in healthy volunteers [105–107] and in patients
with breast cancer [108, 109]. Following oral administra-
tion, letrozole is rapidly and completely absorbed (mean
absolute bioavailability of 99.9%) and extensively distrib-
uted to tissues. It has a large apparent volume of
distribution at steady state (1.87 l/kg [range, 1.47–3.24]),
and approximately 60% is bound to plasma proteins,
mainly to albumin (55%). The terminal half-life (T1/2)o f
letrozole is 42 h. The terminal T1/2 was observed to be
longer and area under the curve (AUC) greater in patients
with breast cancer than in healthy volunteers, possibly due
to reduction in metabolic clearance [109]. The major route
of elimination of letrozole is metabolism by CYP-450
isoenzymes (CYP 3A4 and CYP 2A6) into an inactive
carbinol metabolite. Systemic exposure to metabolites is,
Breast Cancer Res Treat (2007) 105:7–17 11
123therefore, low. Steady-state concentrations of letrozole are
reached after 2–6 weeks and maintained for long periods
with no evidence of drug accumulation.
In marked contrast to the ﬁrst-generation AI aminoglu-
tethimide, no signiﬁcant drug interactions have been
reported for letrozole; however, when combined with
tamoxifen, letrozole plasma concentrations are reduced by
between 35% and 40% [110]. Age does not have an effect
on the pharmacokinetics of letrozole. Exposure to letroz-
ole, measured by AUC, is increased in renally impaired
subjects but remains in the range seen in subjects without
impaired function. However, hepatic impairment can
markedly increase the T1/2 of letrozole, and caution is
required in such patients.
Differences in pharmacokinetics, including uptake rates,
elimination T1/2, and metabolism and clearance exist
between AIs and have been reviewed by Lønning et al.
[111]. The clinical signiﬁcance of such differences is not
known.
Clinical development of letrozole
Letrozole entered clinical trials on the basis of its high
potency and selectivity for aromatase, the demonstration of
unsurpassed anti-tumor effects in models of human breast
cancer, and the development of a convenient oral formu-
lation. Daily doses of 0.1–5 mg have been shown to
suppress estradiol, estrone, and estrone sulfate plasma
concentrations by 75–95% from baseline, while doses
[0.5 mg suppress estrogens to below limit of detection
[92, 112, 113]. Based on pharmacokinetic and pharmaco-
dynamic studies, the recommended dose of letrozole is one
2.5 mg tablet once daily.
Preclinical models [97, 101] successfully predicted that
letrozole would be superior to tamoxifen, the previous gold
standard in the treatment of breast cancer. An extensive
program of clinical trials has been conducted with letrozole
across the spectrum of hormone-responsive breast cancer in
postmenopausal women. The ﬁrst randomized controlled
trials demonstrated consistent superiority for letrozole
compared with megestrol acetate, aminoglutethimide, and
tamoxifen in patients with advanced breast cancer [114–
118]. The clinical efﬁcacy of letrozole in advanced breast
cancer is described in a review by Dr. Mouridsen in this
supplement.
Preclinical MCF-7Ca models have also predicted that
letrozole should be clinically more effective than other less
potent third-generation AIs [99, 102]. Letrozole (2.5 mg/
day) and anastrozole (1 mg/day) were directly compared in
a randomized, open-label phase IIIb/IV study involving
713 postmenopausal women with advanced breast cancer
previously treated with an anti-estrogen [119]. While there
was no difference between the treatment arms in the time
to progression, letrozole produced a signiﬁcantly higher
overall response rate than anastrozole (19.1 vs. 12.3%,
P = 0.013). Letrozole and anastrozole are currently being
compared in a large randomized head-to-head trial in early
breast cancer (ClinicalTrials.gov identiﬁer NCT00248170)
[120]. A review by O’Shaughnessy in this supplement
provides the rationale for this trial and a description of its
design.
The clinical beneﬁts of letrozole in early breast cancer
have already been demonstrated in landmark randomized
clinical trials. MA.17 was the ﬁrst trial to show improved
clinical outcomes with extended adjuvant hormone therapy
[121]. In this trial, letrozole given after initial adjuvant
therapy with tamoxifen signiﬁcantly improved disease-free
survival compared with placebo [121, 122]. Full details of
this trial are provided in a review by Dr. Goss in this
supplement.
Subsequently, the Breast International Group 1-98
trial provided high-level evidence for the superiority of
letrozole over tamoxifen as initial adjuvant therapy [123].
A detailed description of this ongoing trial, which will also
help to deﬁne the optimal sequence for hormone therapies
in hormone-responsive early breast cancer, is provided in a
review by Dr. Thu ¨rlimann in this supplement. Letrozole
has also demonstrated superior efﬁcacy compared with
tamoxifen when used as neoadjuvant therapy [124]. This
treatment setting is particularly interesting in terms of drug
development because the effects of hormone therapy on
breast tumors can be detected early and may be predictive
of long-term outcome [125].
Conclusions
Letrozole is a highly potent and selective AI that inhibits
the enzyme activity of intracellular aromatase at the major
sites where it is found, resulting in almost complete sup-
pression of whole body aromatization. By effectively
blocking estrogen synthesis, letrozole inhibits the growth
or induces the regression of hormone-responsive breast
tumors in vivo. Estrogen is implicated as a major risk
factor in the majority of breast cancers; therefore, use of
the most potent AI is a logical treatment strategy.
Studies conducted using in vitro and in vivo models
have demonstrated that letrozole is the most potent of the
third-generation AIs. Preclinical data obtained from MCF-
7Ca xenograft models suggest that the greater potency of
letrozole compared with anastrozole and exemestane may
translate into clinically meaningful differences in post-
menopausal women with hormone-responsive breast
cancer. These models accurately predicted that letrozole
would be more effective than tamoxifen in the clinical
12 Breast Cancer Res Treat (2007) 105:7–17
123setting. The superiority of letrozole over tamoxifen has
been consistently demonstrated in advanced and early
breast cancer [118, 123]. Outstanding clinical questions,
including what is the most effective AI and what is the
optimal sequence for adjuvant hormonal therapy, will be
answered by the results of ongoing trials involving
letrozole.
In conclusion, experimental data indicating that letrozole
efﬁciently inhibits aromatase activity have been conﬁrmed
clinically, leading to approved indications across the spec-
trum of breast cancer. The broad range of indications for
letrozole in unique clinical settings is reshaping the man-
agement of hormone-sensitive breast cancer.
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